
Adagene (ADAG) Stock Forecast & Price Target
Adagene (ADAG) Analyst Ratings
Bulls say
Adagene is compelling fundamentally because its SAFEbody platform appears to expand the therapeutic window of CTLA-4 and T-cell engager biology, enabling high-dose immune activation with potentially better tolerability than unmasked antibodies. The case is strengthened by muzastotug’s encouraging Phase 1b signals, where management attributes the rising response rate to dose, plus supportive HCC triplet data showing 66.7% ORR versus 32.5% for control and no clear high-grade toxicity penalty. Beyond clinical data, the company has meaningful optionality from partnerships and cash support, including a $2.0M Exelixis milestone, Third Arc funding of development, and an extended runway into 2H28.
Bears say
Adagene is exposed to significant clinical-risk because ADG126’s encouraging 36% ORR comes from only n=14 in small, non-randomized cohorts, with no monotherapy or pembrolizumab-only control to isolate its contribution. The safety profile remains concerning, as grade 3 TRAEs reached 50% and grade 3 diarrhea/colitis 29%, while prior masked CTLA-4 programs have shown mixed or disappointing results in MSS CRC, where single-arm signals often fade in randomized testing. Financially, the company’s ~$122M net cash appears insufficient for registrational-scale metastatic and potential neoadjuvant development, increasing the likelihood of additional financing, dilution, or dependence on partnering amid regulatory and China-related execution risks.
This aggregate rating is based on analysts' research of Adagene and is not a guaranteed prediction by Public.com or investment advice.
Adagene (ADAG) Analyst Forecast & Price Prediction
Start investing in Adagene (ADAG)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Adagene (ADAG) Forecast
Adagene (ADAG) Analyst Forecast & Price Prediction
Start investing in Adagene (ADAG)
Order type
Buy in
Order amount
Est. shares
0 shares